Frank Sinicrope/X
Jun 29, 2025, 07:54
Frank Sinicrope: FOLFOX + Atezolizumab is Now Incorporated Into The NCCN Guidelines for dMMR Colon Cancer
Frank Sinicrope, Clinical Investigator of the Mayo Foundation and Co-leader GI Cancer Program at Mayo Clinic Rochester, shared a post on X:
“For dMMR colon cancer, FOLFOX + atezolizumab per ATOMIC is now incorporated into the NCCN Guidelines.”
More posts featuring Frank Sinicrope.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 13, 2025, 15:15
Aug 13, 2025, 15:14
Aug 13, 2025, 15:10
Aug 13, 2025, 15:09
Aug 13, 2025, 15:05
Aug 13, 2025, 14:38
Aug 13, 2025, 14:34
Aug 13, 2025, 14:30